Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Oct 20;89(8):1439-44.
doi: 10.1038/sj.bjc.6601310.

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly

T Aparicio  1 , J Desramé, T Lecomte, E Mitry, J Belloc, I Etienney, S Montembault, L Vayre, C Locher, J Ezenfis, P Artru, M Mabro, S Dominguez; AGEO
Affiliations
Clinical Trial

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly

T Aparicio et al. Br J Cancer. .

Abstract

The tolerance and efficacy of oxaliplatin and irinotecan for metastatic colorectal cancer are unknown in elderly patients. Methods. All consecutive patients over 74 years treated with oxaliplatin or irinotecan for metastatic colorectal cancer were enrolled. The tumour response was assessed every 2-3 months and toxicity was collected at each cycle according to World Health Organisation criteria. A total of 66 patients were enrolled from 12 centres. The median age was 78 years (range, 75-88 years); 39 patients had no severe comorbidity according to the Charlson score. In total, 44 and 22 patients received oxaliplatin or irinotecan, respectively, in combination with 5-fluororuracil+/-folinic acid or raltitrexed in 64 patients. A total of 545 chemotherapy cycles were administered in first (41%), second (51%) or third line (8%). A dose reduction occurred in 190 cycles (35%). Complete response, partial response and stabilisation occurred in 1.5, 20 and 47% of patients, respectively. The median time to progression and overall survival were 6.8 and 11.2 months in first line and 6.3 and 11.6 months in second line, respectively. Grade 3 and 4 toxicity occurred in 42% of patients: neutropenia 17%, diarrhoea 15%, neuropathy 11%, nausea and vomiting 8% and thrombopenia 6%. There was no treatment-related death. In selected elderly patients, chemotherapy with oxaliplatin or irinotecan is feasible with manageable toxicity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PFS curve.
Figure 2
Figure 2
PFS curves according to age group.
Figure 3
Figure 3
OS curve.
Figure 4
Figure 4
OS curves according to age group.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Andre T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F, Beerblock K, Bouche O, Carola E, Merrouche Y, Morvan F, Dupont-Andre G, de Gramont A (1999) Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17: 3560–3568 - PubMed
    1. Beretta G, Bolina R, Cozzi C (1997) Should we consider the weekly (w) chemotherapy (CT) with fluorouracil (F)+racemic folinic acid (f) a standard treatment for advanced/metastatic carcinoma of digestive tract (DTC) in elderly patients (pts)? Proc Am Soc Clin Oncol 16: 259a
    1. Bray F, Sankila R, Ferlay J, Parkin DM (2002) Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38: 99–166 - PubMed
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373–383 - PubMed
    1. Chiara S, Nobile MT, Vincenti M, Lionetto R, Gozza A, Barzacchi MC, Sanguineti O, Repetto L, Rosso R (1998) Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 42: 336–340 - PubMed

MeSH terms